Distinct from IMLYGIC®, the mechanism of action of Gendicine® depends on the expression of p53 protein in tumor cells that initiates apoptotic pathways, suppresses anti‐apoptotic events, and blocks the survival pathways.5 This evidence concerns the gene TP53 and neoplasm.